#ESMO26 Presidential 1
Excellent state-of-the art discussion on #Dellphi-305 by the 1@only @StephenVLiu
emphasizing on:
➡️ 1L maintenance Tarla setting a new SoC with a mOS of>20 months
❓High attrition rate from induction to maintenance, need for earlier TCE ( Dellphi-312)
❌Only 19% of pts in control arm received 2L Tarla post-progression reflecting access hurdles
✅ Global access to Tarla will make innovation meaningful for our patients
@@myESMO #ESMOAmbassadors
235 views · 7 likes · 2 reposts · 0 replies
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Giannis Mountzios · x.com
